575 Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody

MLA

Rong Wu, et al. “575 Preclinical Characterization of LAE111, a Potent Anti-LILRB1/LILRB2 Antagonist Bispecific Antibody.” Journal for ImmunoTherapy of Cancer, vol. 11, no. Suppl 1, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-SITC2023.0575.

APA

Rong Wu, Xiang-Ju Justin Gu, Minhua Zhang, & Chaojun Cai. (2023). 575 Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody. Journal for ImmunoTherapy of Cancer, 11(Suppl 1). https://doi.org/10.1136/jitc-2023-SITC2023.0575

Chicago

Rong Wu, Xiang-Ju Justin Gu, Minhua Zhang, and Chaojun Cai. 2023. “575 Preclinical Characterization of LAE111, a Potent Anti-LILRB1/LILRB2 Antagonist Bispecific Antibody.” Journal for ImmunoTherapy of Cancer 11 (Suppl 1). doi:10.1136/jitc-2023-SITC2023.0575.